238 related articles for article (PubMed ID: 11423669)
1. STI571: targeting BCR-ABL as therapy for CML.
Mauro MJ; Druker BJ
Oncologist; 2001; 6(3):233-8. PubMed ID: 11423669
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
Wolff NC; Ilaria RL
Blood; 2001 Nov; 98(9):2808-16. PubMed ID: 11675355
[TBL] [Abstract][Full Text] [Related]
3. Targeted chronic myeloid leukemia therapy: seeking a cure.
Fausel C
J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
[TBL] [Abstract][Full Text] [Related]
4. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
Nakajima M; Toga W
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
[TBL] [Abstract][Full Text] [Related]
5. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
Topaly J; Zeller WJ; Fruehauf S
Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
[TBL] [Abstract][Full Text] [Related]
6. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
Buchdunger E
Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
[TBL] [Abstract][Full Text] [Related]
7. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
[TBL] [Abstract][Full Text] [Related]
8. Chronic myelogenous leukemia in chronic phase.
Kurzrock R; Kantarjian H; Talpaz M
Curr Treat Options Oncol; 2001 Jun; 2(3):245-52. PubMed ID: 12057124
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction.
Stentoft J; Pallisgaard N; Kjeldsen E; Holm MS; Nielsen JL; Hokland P
Eur J Haematol; 2001; 67(5-6):302-8. PubMed ID: 11872078
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Druker BJ; Talpaz M; Resta DJ; Peng B; Buchdunger E; Ford JM; Lydon NB; Kantarjian H; Capdeville R; Ohno-Jones S; Sawyers CL
N Engl J Med; 2001 Apr; 344(14):1031-7. PubMed ID: 11287972
[TBL] [Abstract][Full Text] [Related]
11. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.
Hernández-Boluda JC; Cervantes F
Drugs Today (Barc); 2002 Sep; 38(9):601-13. PubMed ID: 12582448
[TBL] [Abstract][Full Text] [Related]
13. STI571 as a targeted therapy for CML.
O'Dwyer ME; Mauro MJ; Druker BJ
Cancer Invest; 2003 Jun; 21(3):429-38. PubMed ID: 12901289
[TBL] [Abstract][Full Text] [Related]
14. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.
Roche-Lestienne C; Soenen-Cornu V; Grardel-Duflos N; Laï JL; Philippe N; Facon T; Fenaux P; Preudhomme C
Blood; 2002 Aug; 100(3):1014-8. PubMed ID: 12130516
[TBL] [Abstract][Full Text] [Related]
15. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
16. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
[TBL] [Abstract][Full Text] [Related]
17. [STI571: a summary of targeted therapy].
Czyz M; Jakubowska J
Postepy Hig Med Dosw (Online); 2006; 60():677-96. PubMed ID: 17245318
[TBL] [Abstract][Full Text] [Related]
18. [Antileukemic drug--a selective inhibitor of BCR-ABL tyrosine kynase, imatinib(STI571)].
Jinnai I
Nihon Rinsho; 2002 Jan; 60(1):88-94. PubMed ID: 11808344
[TBL] [Abstract][Full Text] [Related]
19. Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.
Sillaber C; Mayerhofer M; Agis H; Sagaster V; Mannhalter C; Sperr WR; Geissler K; Valent P
Wien Klin Wochenschr; 2003 Aug; 115(13-14):485-504. PubMed ID: 13677268
[TBL] [Abstract][Full Text] [Related]
20. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Verstovsek S; Giles F; Rios MB; Shan J; Letvak L; Thomas D; Faderl S; Ferrajoli A; Cortes J
Blood; 2004 Apr; 103(8):2873-8. PubMed ID: 15070658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
